New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
16:13 EDTQGENQIAGEN announces three separate agreements to add biomarkers
QIAGEN announced three separate agreements that add multiple biomarkers to QIAGEN's development pipeline of diagnostics for Personalized Healthcare applications. QIAGEN intends to develop new diagnostics to guide treatment decisions, including companion diagnostics paired with medicines, based on these biomarkers. Most of these assays will be designed to run on the QIAsymphony RGQ modular laboratory workflow automation system as well as QIAGEN's next-generation sequencing workflows currently in development. QIAGEN has made a strategic equity investment in Drug Response Dx GmbH with the option to obtain worldwide rights to biomarkers for evaluation of rheumatoid arthritis patients to guide treatment with TNF-alpha inhibitors, which are widely prescribed for treatment of RA. QIAGEN has agreed to license exclusive worldwide rights from Insight Genetics for the RET, ROS1 and DEPDC1 biomarkers for use in non-small cell lung cancer, the most common form of lung cancer. QIAGEN Marseille has licensed exclusive worldwide rights to a biomarker for mutations of the HSP110 gene, which allows for identification of specific types of colorectal cancer, from InsermTransfert, the technology transfer arm of the French National Institute of Health and Medical Research.
News For QGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 16, 2015
16:07 EDTQGENTokai Pharmaceuticals expands collaboration with QIAGEN
Subscribe for More Information
16:06 EDTQGENQIAGEN acquires circulating tumor cell technology from AdnaGen
QIAGEN (QGEN) announced an expansion of itsportfolio of liquid biopsies through the acquisition of an technology that enables enrichment and molecular analysis of circulating tumor cells from blood samples. The proprietary technology from AdnaGen allows a complete solution for the detection and analysis of CTCs for clinical applications. QIAGEN also announced a new partnership with Tokai Pharmaceuticals (TKAI) to combine this new CTC technology with a molecular assay to co-develop and commercialize a companion diagnostic for Tokai's novel drug compound galeterone, which is in late-stage clinical trials for treatment of castration-resistant prostate cancer. The non-invasive test will determine the expression of the AR-V7 biomarker, which in recent studies has demonstrated potential utility to guide therapy choice in CRPC patients. Financial terms for the AdnaGen acquisition and the Tokai partnership were not disclosed.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use